Ask AI
ProCE Banner Activity

Promising Strategies on the Horizon for HR+/HER2- MBC

Slideset Download
Download this slideset to explore future directions in the treatment of HR+/HER2- metastatic breast cancer, including what to do after progression on a CDK4/6 inhibitor and a review of novel agents in the setting of resistance to standard-of-care therapies.

Released: May 31, 2019

Expiration: May 29, 2020

Share

Supporters

This activity is supported by independent educational grants from

Lilly

Novartis Pharmaceuticals Corporation

Faculty Disclosure

Primary Author

Adam M. Brufsky, MD, PhD

Associate Professor
Department of Medicine, Division of Hematology/Oncology
University of Pittsburgh
Pittsburgh, Pennsylvania